Saturday, September 19, 2009
Thursday, September 17, 2009
Tuesday, September 15, 2009
However, it is important
to acknowledge that the overall effect sizes are relatively
small and that causality has not been absolutely
established. We would like to highlight that this meta-analysis
does not support a need for patients and their families
to feel responsible for their disease outcome if they experience
depression. It has become accepted in popular culture
that cancer patients need to maintain a positive attitude to
heroically defeat cancer, a recommendation that Spiegel and
Giese-Davis have termed an ‘‘emotional straightjacket.’’
Even if one did ascribe to this belief, the magnitude of the
effect of depression on mortality does not seem to warrant
the assignment of responsibility and blame to cancer
The Edmonton symptom assessment system--what do pa...[Support Care Cancer. 2009] - PubMed Result: "Patients expressed a need to emphasize the timeframe as 'now'."
Monday, September 14, 2009
Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma -- Garg and Soslow 62 (8): 679 -- Journal of Clinical Pathology
Traditionally Lynch syndrome has been perceived as a CRC dominated syndrome. However, in women with Lynch syndrome, the incidence of EC equals or exceeds that of CRC2 and in more than 50% of cases, these women present with a gynaecological cancer as their first or "sentinel" malignancy.
Fabry trial set to answer "political problem" -- Silversides 181 (67): 365 -- Canadian Medical Association Journal
Fabry trial set to answer "political problem" -- Silversides 181 (67): 365 -- Canadian Medical Association Journal: "'Patients have become pawns; they are really tossed around like ping pong balls,'"
Sunday, September 13, 2009
Friday, September 11, 2009
FDA Clears a Test for Ovarian Cancer | Reuters: "OVA1 should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures. OVA1 uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant. OVA1 is intended only for women, 18 years and older, who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal."
Thursday, September 10, 2009
Clinical Care Options Oncology - Ovarian Cancer—Recent Developments in the Standard of Care and Emerging Options
Clinical Care Options Oncology - Ovarian Cancer—Recent Developments in the Standard of Care and Emerging Options: "Virtual Presentations
I. Frontline Management—IP and Maintenance Therapy
II. Rising CA-125: To Treat or Not to Treat?"